Voyager Therapeutics Inc (VYGR)
8.43
-0.20
(-2.32%)
USD |
NASDAQ |
May 17, 16:00
8.43
0.00 (0.00%)
After-Hours: 20:00
Voyager Therapeutics Cash from Investing (Quarterly): -96.06M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -96.06M |
| December 31, 2023 | 26.83M |
| September 30, 2023 | -158.30M |
| June 30, 2023 | -24.66M |
| March 31, 2023 | 14.49M |
| December 31, 2022 | 14.07M |
| September 30, 2022 | 34.72M |
| June 30, 2022 | -36.13M |
| March 31, 2022 | -20.00M |
| December 31, 2021 | -5.464M |
| September 30, 2021 | 14.34M |
| June 30, 2021 | 22.40M |
| March 31, 2021 | 34.62M |
| December 31, 2020 | -21.52M |
| September 30, 2020 | 27.36M |
| June 30, 2020 | -1.838M |
| March 31, 2020 | 108.99M |
| December 31, 2019 | 26.46M |
| September 30, 2019 | 22.61M |
| Date | Value |
|---|---|
| June 30, 2019 | -2.888M |
| March 31, 2019 | -136.66M |
| December 31, 2018 | 28.63M |
| September 30, 2018 | -1.193M |
| June 30, 2018 | -59.37M |
| March 31, 2018 | 58.40M |
| December 31, 2017 | -60.10M |
| September 30, 2017 | -2.768M |
| June 30, 2017 | 38.53M |
| March 31, 2017 | 20.66M |
| December 31, 2016 | -13.72M |
| September 30, 2016 | 6.611M |
| June 30, 2016 | 42.76M |
| March 31, 2016 | 12.07M |
| December 31, 2015 | -99.58M |
| September 30, 2015 | -10.51M |
| June 30, 2015 | -84.53M |
| March 31, 2015 | -0.15M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-158.30M
Minimum
Sep 2023
108.99M
Maximum
Mar 2020
-0.9981M
Average
14.20M
Median
Cash from Investing (Quarterly) Benchmarks
| Ligand Pharmaceuticals Inc | -3.775M |
| Stereotaxis Inc | 0.00 |
| United Therapeutics Corp | 735.30M |
| MEI Pharma Inc | 0.122M |
| Agios Pharmaceuticals Inc | 124.56M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 58.77M |
| Cash from Financing (Quarterly) | 112.86M |
| Free Cash Flow | 8.233M |
| Free Cash Flow Per Share (Quarterly) | 0.9914 |
| Free Cash Flow to Equity (Quarterly) | 56.63M |
| Free Cash Flow to Firm (Quarterly) | 56.63M |
| Free Cash Flow Yield | 2.00% |